A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 02 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Budigalimab (Primary) ; Livmoniplimab (Primary) ; Carboplatin; Cisplatin; Pembrolizumab; Pemetrexed
Indications Anaplastic large cell lymphoma; Non-small cell lung cancer
Focus Therapeutic Use
Acronyms LIVIGNO-4
Sponsors AbbVie

Most Recent Events

28 Nov 2024 Planned End Date changed from 8 Oct 2031 to 1 Oct 2031.
28 Nov 2024 Planned primary completion date changed from 8 Oct 2031 to 1 Oct 2031.
17 Sep 2024 According to Trial design presented at the 49th European Society for Medical Oncology Congress, enrollment is ongoing in approx. 200 sites globally.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight